𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma

✍ Scribed by Neal J. Meropol; Nicholas J. Petrelli; Youcef M. Rustum; Miguel Rodriguez-Bigas; Leslie E. Blumenson; Cheryl Frank; Elmer Berghorn; Patrick J. Creaven

Publisher
Springer US
Year
1995
Tongue
English
Weight
529 KB
Volume
13
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of chemotherapy of meta
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin
✍ Robert P. Whitehead; Thomas R. Fleming; John S. Macdonald; Frederick R. Ahmann; πŸ“‚ Article πŸ“… 1991 πŸ› Springer US 🌐 English βš– 205 KB

The combination of 5-fluorouracil and cisplatin has shown encouraging results in single institution pilot studies in colorectal carcinoma. This phase II SWOG study was undertaken to further evaluate this treatment. Cisplatin was administered at a dose of 60 mg/M2 IV day 1, repeated every 21 days. 5-

A comprehensive review of 5-fluorouracil
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
✍ David Machover πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 112 KB πŸ‘ 2 views

## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; AndrΓ©s Cervantes; Javier Dorta; Esperanza Blanco; Carlos FernΓ‘nd πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 419 KB πŸ‘ 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer